BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20672385)

  • 1. Lynch syndrome-associated mutations in MSH2 alter DNA repair and checkpoint response functions in vivo.
    Mastrocola AS; Heinen CD
    Hum Mutat; 2010 Oct; 31(10):E1699-708. PubMed ID: 20672385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional analysis of HNPCC-related missense mutations in MSH2.
    Lützen A; de Wind N; Georgijevic D; Nielsen FC; Rasmussen LJ
    Mutat Res; 2008 Oct; 645(1-2):44-55. PubMed ID: 18822302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel pathogenic MSH2 mutation and new DNA repair genes variants: investigation of a Tunisian Lynch syndrome family with discordant twins.
    Jaballah-Gabteni A; Tounsi H; Kabbage M; Hamdi Y; Elouej S; Ben Ayed I; Medhioub M; Mahmoudi M; Dallali H; Yaiche H; Ben Jemii N; Maaloul A; Mezghani N; Abdelhak S; Hamzaoui L; Azzouz M; Boubaker S
    J Transl Med; 2019 Jun; 17(1):212. PubMed ID: 31248416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Truncation of the MSH2 C-terminal 60 amino acids disrupts effective DNA mismatch repair and is causative for Lynch syndrome.
    Wielders E; Delzenne-Goette E; Dekker R; van der Valk M; Te Riele H
    Fam Cancer; 2017 Apr; 16(2):221-229. PubMed ID: 27873144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidating the molecular basis of MSH2-deficient tumors by combined germline and somatic analysis.
    Vargas-Parra GM; González-Acosta M; Thompson BA; Gómez C; Fernández A; Dámaso E; Pons T; Morak M; Del Valle J; Iglesias S; Velasco À; Solanes A; Sanjuan X; Padilla N; de la Cruz X; Valencia A; Holinski-Feder E; Brunet J; Feliubadaló L; Lázaro C; Navarro M; Pineda M; Capellá G
    Int J Cancer; 2017 Oct; 141(7):1365-1380. PubMed ID: 28577310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional analysis of MSH2 unclassified variants found in suspected Lynch syndrome patients reveals pathogenicity due to attenuated mismatch repair.
    Wielders EA; Hettinger J; Dekker R; Kets CM; Ligtenberg MJ; Mensenkamp AR; van den Ouweland AM; Prins J; Wagner A; Dinjens WN; Dubbink HJ; van Hest LP; Menko F; Hogervorst F; Verhoef S; te Riele H
    J Med Genet; 2014 Apr; 51(4):245-53. PubMed ID: 24501230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay.
    Bianchi F; Maccaroni E; Belvederesi L; Brugiati C; Giampieri R; Bini F; Bracci R; Pagliaretta S; Del Prete M; Piva F; Mandolesi A; Scarpelli M; Berardi R
    Fam Cancer; 2018 Apr; 17(2):215-224. PubMed ID: 28785832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional interrogation of Lynch syndrome-associated MSH2 missense variants via CRISPR-Cas9 gene editing in human embryonic stem cells.
    Rath A; Mishra A; Ferreira VD; Hu C; Omerza G; Kelly K; Hesse A; Reddi HV; Grady JP; Heinen CD
    Hum Mutat; 2019 Nov; 40(11):2044-2056. PubMed ID: 31237724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of pathogenicity in human MSH2 missense mutants.
    Ollila S; Dermadi Bebek D; Jiricny J; Nyström M
    Hum Mutat; 2008 Nov; 29(11):1355-63. PubMed ID: 18951462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline MLH1, MSH2 and MSH6 variants in Brazilian patients with colorectal cancer and clinical features suggestive of Lynch Syndrome.
    Schneider NB; Pastor T; Paula AE; Achatz MI; Santos ÂRD; Vianna FSL; Rosset C; Pinheiro M; Ashton-Prolla P; Moreira MÂM; Palmero EI;
    Cancer Med; 2018 May; 7(5):2078-2088. PubMed ID: 29575718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation Tolerance-Based Functional Assay to Assess Variants of Unknown Significance in the MLH1 and MSH2 Genes and Identify Patients With Lynch Syndrome.
    Bouvet D; Bodo S; Munier A; Guillerm E; Bertrand R; Colas C; Duval A; Coulet F; Muleris M
    Gastroenterology; 2019 Aug; 157(2):421-431. PubMed ID: 30998989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein.
    Ollila S; Sarantaus L; Kariola R; Chan P; Hampel H; Holinski-Feder E; Macrae F; Kohonen-Corish M; Gerdes AM; Peltomäki P; Mangold E; de la Chapelle A; Greenblatt M; Nyström M
    Gastroenterology; 2006 Nov; 131(5):1408-17. PubMed ID: 17101317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MSH2 c.1022T>C, p.Leu341Pro is a founder pathogenic variation and a major cause of Lynch syndrome in the North of France.
    Vermaut C; Leclerc J; Vasseur F; Wacrenier A; Lovecchio T; Boidin D; Rebergue MH; Cattan S; Manouvrier S; Lejeune S; Buisine MP
    Genes Chromosomes Cancer; 2020 Feb; 59(2):111-118. PubMed ID: 31433521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants.
    Houlleberghs H; Dekker M; Lantermans H; Kleinendorst R; Dubbink HJ; Hofstra RM; Verhoef S; Te Riele H
    Proc Natl Acad Sci U S A; 2016 Apr; 113(15):4128-33. PubMed ID: 26951660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The spectrum of Lynch syndrome-associated germ-line mutations in Russia.
    Yanus GA; Akhapkina TA; Iyevleva AG; Kornilov AV; Suspitsin EN; Kuligina ES; Ivantsov AO; Aleksakhina SN; Sokolova TN; Sokolenko AP; Togo AV; Imyanitov EN
    Eur J Med Genet; 2020 Mar; 63(3):103753. PubMed ID: 31491536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The First Molecular Screening of MLH1 and MSH2 Genes in Moroccan Colorectal Cancer Patients Shows a Relatively High Mutational Prevalence.
    Moufid FZ; Bouguenouch L; El Bouchikhi I; Chbani L; Iraqui Houssaini M; Sekal M; Belhassan K; Bennani B; Ouldim K
    Genet Test Mol Biomarkers; 2018 Aug; 22(8):492-497. PubMed ID: 30044143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Massively parallel functional testing of MSH2 missense variants conferring Lynch syndrome risk.
    Jia X; Burugula BB; Chen V; Lemons RM; Jayakody S; Maksutova M; Kitzman JO
    Am J Hum Genet; 2021 Jan; 108(1):163-175. PubMed ID: 33357406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
    Berginc G; Bracko M; Ravnik-Glavac M; Glavac D
    Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Genetic analysis of 45 patients with suspected Lynch syndrome using next-generation sequencing].
    Yao ZG; Cheng XK; Lin CH; Li J; Lyu BB; Li JM; Jing HY; Qin YJ; Sun XC
    Zhonghua Zhong Liu Za Zhi; 2021 Aug; 43(8):843-849. PubMed ID: 34407589
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.